EBV-miR-BART7-3p Imposes Stemness in Nasopharyngeal Carcinoma Cells by Suppressing SMAD7

Longmei Cai1,2, Yufei Long1, Tuotuo Chong1

  • 1Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen, China.

Frontiers in Genetics
|November 5, 2019
PubMed

Insights

Epstein-Barr virus microRNA (EBV-miR-BART7-3p) promotes cancer stemness in nasopharyngeal carcinoma (NPC) by suppressing SMAD7. This viral microRNA enhances drug resistance and recurrence, offering potential therapeutic targets.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Cancer stem-like cells drive tumor progression, metastasis, and drug resistance.
  • Viral microRNAs, like EBV-miR-BART7-3p, can regulate cancer malignancy.
  • Nasopharyngeal carcinoma (NPC) progression is linked to viral factors.

Purpose of the Study:

  • To investigate the role of EBV-miR-BART7-3p in inducing stemness in NPC cells.
  • To identify the molecular mechanisms by which EBV-miR-BART7-3p promotes stemness.
  • To evaluate the impact of EBV-miR-BART7-3p on chemo-resistance and recurrence in NPC.

Main Methods:

  • Assessed stemness markers, side population cells, and tumor sphere formation in vitro.
  • Evaluated cancer-initiating properties in vivo.
  • Identified and validated SMAD7 as a target gene of EBV-miR-BART7-3p.
  • Investigated the role of TGF-β signaling pathway.
  • Assessed chemo-resistance in vitro and in vivo.

Main Results:

  • EBV-miR-BART7-3p significantly increased NPC cell stemness markers, side population, and tumor sphere formation.
  • EBV-miR-BART7-3p suppressed SMAD7, leading to TGF-β pathway activation and enhanced stemness.
  • Silencing SMAD7 mimicked EBV-miR-BART7-3p effects; SMAD7 reconstitution reversed them.
  • EBV-miR-BART7-3p conferred chemo-resistance in vitro and in vivo.
  • EBV-positive NPC cells showed increased stem-like properties and chemo-resistance.

Conclusions:

  • EBV-miR-BART7-3p is a key driver of stemness in NPC cells.
  • The EBV-miR-BART7-3p/SMAD7/TGF-β axis is a novel mechanism promoting NPC stemness and chemo-resistance.
  • Targeting EBV-miR-BART7-3p or SMAD7 may offer therapeutic strategies against NPC recurrence and drug resistance.